Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Assets (2016 - 2025)

Integra Lifesciences Holdings' Assets history spans 17 years, with the latest figure at $3.6 billion for Q4 2025.

  • For Q4 2025, Assets fell 10.78% year-over-year to $3.6 billion; the TTM value through Dec 2025 reached $3.6 billion, down 10.78%, while the annual FY2025 figure was $3.6 billion, 10.78% down from the prior year.
  • Assets for Q4 2025 was $3.6 billion at Integra Lifesciences Holdings, down from $3.6 billion in the prior quarter.
  • Across five years, Assets topped out at $4.1 billion in Q1 2024 and bottomed at $3.6 billion in Q4 2025.
  • The 5-year median for Assets is $3.8 billion (2023), against an average of $3.8 billion.
  • The largest annual shift saw Assets rose 9.46% in 2021 before it decreased 10.78% in 2025.
  • A 5-year view of Assets shows it stood at $3.8 billion in 2021, then rose by 2.84% to $3.9 billion in 2022, then fell by 2.77% to $3.8 billion in 2023, then grew by 6.75% to $4.0 billion in 2024, then fell by 10.78% to $3.6 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Assets are $3.6 billion (Q4 2025), $3.6 billion (Q3 2025), and $3.7 billion (Q2 2025).